Core Viewpoint - Novo Nordisk (NVO.US) experienced a significant drop of nearly 16%, trading at $39.97, while Eli Lilly (LLY.US) saw an increase of over 4%, trading at $1055.47. This market reaction follows Novo Nordisk's announcement that its weight loss drug Cagrisema showed less effective results compared to Eli Lilly's Zepbound [1]. Company Summary - Novo Nordisk's Cagrisema drug trial results were disappointing, leading to a sharp decline in its stock price [1]. - Eli Lilly's Zepbound demonstrated superior efficacy in comparison to Cagrisema, contributing to Eli Lilly's stock price increase [1].

Group 1 - The U.S. trade policy outlook remains uncertain, leading to negative market sentiment and a collective decline in major U.S. stock indices [1] - The Nasdaq Composite fell by 0.03%, the Dow Jones Industrial Average decreased by 0.31%, and the S&P 500 index dropped by 0.03% [1] - Technology stocks experienced widespread declines, with Tesla and Oracle both falling over 1% [1] Group 2 - Novo Nordisk's stock plummeted by 15% due to disappointing trial results for its new weight loss drug CagriSema, which underperformed compared to Eli Lilly's Zepbound [1]

Group 1 - United Airlines fell by 1.7%, American Airlines dropped by 1.1%, and Delta Airlines decreased by 1.5% due to a severe snowstorm that forced airlines to cancel flights nationwide [1] - Arcellx surged by 78.1% as Gilead Sciences announced it would acquire Arcellx at a price of $115 per share [1] - Novo Nordisk declined by 15.6% after its weight loss drug CagriSema showed less effective results compared to Eli Lilly's competing product, which saw an increase of 4.8% [1] - Domino's Pizza rose by 6.0% as its Q4 revenue exceeded expectations [1]

Core Viewpoint - The article highlights the ongoing production activities across various industries in China during the Spring Festival, emphasizing the commitment of companies to maintain supply and meet market demands despite the holiday season [1][3][4]. Group 1: Production Continuity - Over 260 companies in Ningbo and more than 280 industrial enterprises in Luoyang continued production during the Spring Festival, with an increase of approximately 30 companies compared to 2025 [1]. - In Tianjin, around 90 key industrial enterprises maintained continuous production, with an expected overall resumption rate of 86.3% by February 24 [1]. - Sichuan Zhou Hei Ya Food Co., Ltd. reported a daily production of over 50,000 "modified atmosphere packaging" products to ensure supply to stores in multiple regions [1]. Group 2: Market Opportunities - Zhejiang Hengcheng Hard Alloy Co., Ltd. experienced a significant production value increase of 230% year-on-year in January, with over 100 employees working during the holiday to meet tight delivery schedules [3]. - Nanjing Huaxin Fiber Optic Co., Ltd. reported a full operation of 38 fiber optic production lines during the Spring Festival due to high demand, with orders extending into the second half of the year [4]. Group 3: Safety Measures - Guangxi Sun Paper Industry Co., Ltd. implemented strict safety measures during the holiday, including regular inspections and approvals for hazardous operations, to ensure safe production [6]. - The State Council's Work Safety Committee emphasized the importance of safety production during the holiday, focusing on risk prevention in various industries [6]. Group 4: Support and Coordination - The Gansu Lanzhou New Area Project Construction Center coordinated with various departments to address companies' needs, ensuring uninterrupted supply and support during the holiday [7]. - Local governments established 24-hour service hotlines and conducted special visits to ensure continuous production and address any operational challenges faced by enterprises [7].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 increased 65% year-over-year to $196 million, and for the full year increased 66% to $639 million [6][12] - Net product sales of Auvelity for Q4 were $155.1 million, up 68% year-over-year, and total sales for Auvelity reached $507.1 million, representing a 74% year-over-year increase [12][13] - Net loss for Q4 was $28.6 million, or $0.56 per share, compared to a net loss of $74.9 million, or $1.54 per share for Q4 2024 [17] - Cash and cash equivalents at year-end were $323 million, compared to $315 million at the end of 2024 [18] Business Line Data and Key Metrics Changes - Auvelity achieved sales of over $500 million in its third full year of launch, with significant growth in prescriptions [5][20] - Sunosi posted Q4 net product revenue of $36.7 million, a 40% increase compared to Q4 2024, and $124.8 million for the full year, representing a 32% increase [13][25] - Symbravo generated $4.1 million in net sales for Q4 and $6.6 million for the full year, following its second full quarter of launch [14] Market Data and Key Metrics Changes - Auvelity prescriptions grew by 42% year-over-year, with over 225,000 prescriptions written in Q4 [20] - Payer coverage for Auvelity increased from 75% to 78%, bringing total coverage to 86% of all lives across channels [21] - Symbravo's payer coverage is approximately 52% at the start of the year, with ongoing negotiations expected to expand this coverage [24] Company Strategy and Development Direction - The company is focused on scaling growth across its commercial organization and expanding adoption of CNS medicines [25] - A significant expansion of the Auvelity sales force to approximately 600 representatives is planned to support growth in MDD and potential Alzheimer's disease agitation [22][64] - The company is advancing a broad CNS pipeline, including five novel product candidates across nine high-impact indications [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of Auvelity in addressing Alzheimer's disease agitation, with launch readiness activities underway [7][74] - The company anticipates continued momentum in its commercial business and expects to achieve cash flow positivity based on its current operating plan [18] - Management highlighted the importance of ongoing negotiations with payers to ensure access for both MDD and ADA indications [56] Other Important Information - The company has made significant progress in its CNS pipeline, including planned trials for AXS-05 in smoking cessation and AXS-12 in narcolepsy [8][9] - The company acquired AZD7325, a novel oral GABA A receptor modulator, to evaluate for the treatment of epilepsy [10] Q&A Session Summary Question: Implications of the new FDA publication on trial policy - Management is assessing the implications and will continue to vet clinical plans with the FDA [29][30] Question: Development plan for AXS-17 in epilepsy - The product has been studied in various indications, and the focus is currently on preparing for phase II readiness [35][36] Question: Coverage evolution for Auvelity post-ADA label approval - Existing coverage should generally apply to the new indication, but additional efforts are being made for Medicare coverage [40][41] Question: Drivers of Sunosi's growth - Growth is driven by both OSA and narcolepsy markets, with positive trends in new patient starts and prescriber behavior [48] Question: Progress of the DTC campaign for Auvelity - The national TV campaign has generated an inflection in new patient starts, with growth seen in primary care and psychiatry [52][53] Question: Expected reimbursement and market access for Auvelity - The goal is to secure access for as many patients as possible, with steady progress in increasing covered lives [56] Question: Coverage evolution for Symbravo - Secured contracts with large GPOs will facilitate negotiations with payers, with optimism about increasing coverage [68][70] Question: Launch readiness for Alzheimer's disease agitation - The company will be ready to launch within a quarter post-approval, with plans to share metrics on script percentages from the ADA space [74]

小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221）公告，公司已于2月16日与跨国药巨头葛兰素史克（GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品 的全球权益授予GSK。 分工明确 权益清晰 根据公告，此次授权的两款产品中，一款候选药物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 根据协议，前沿生物将负责其中一款产品在中国的I期临床试验推进，以及另一款产品的IND支持性研究；GSK则将主导两款产品后续的全球临床开发、 注册申报及商业化工作。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并有望在后续开发、监管和商业化过程中获得最高9.5亿美元的里程碑付 款，交易总金额累计超过10亿美元。此外，前沿生物还将享有两款产品全球净销售额的分级特许权使用费。 前沿生物在公告中表示，此次合作不仅将为公司带来可观的现金流支持，助力核心研发投入与技术平台升级，也标志着其在小核酸药物领域的技术实力获 得国际认可。公司在此次合作中将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓 展全球 ...

1. 2月23日(周一)美股盘前，美股三大股指 期货齐跌。截至发稿，道指期货跌0.42%，标普期货跌 0.46%，纳指期货跌0.62%。 2. 截至发稿，欧洲股市主要指数涨跌互现。欧洲斯托克50指数跌0.12%，英 国富时100指数涨0.09%，法国CAC40指数跌0.01%，德国DAX30指数跌0.5%。 3. 截至发稿，WTI原油 涨0.21%，报66.62美元/桶。布伦特原油涨0.21%，报71.45美元/桶。纽交所 黄金涨1.74%，报5169.5美 元/盎司。 市场消息 1、特朗普称美国最高法院裁决无意间赋予其更多权力，可更强大使用关税措施。 2、欧盟势将冻结对与美国贸易协议的批准程序，欧盟特使将于周一下午开会讨论相关贸易问题。 3、 英国央行货币政策委员泰勒表示还需2到3次降息，美国高额关税政策将长期持续。 4、国际现货黄金和 白银价格显著上涨，伦敦现货黄金逼近5200美元/盎司。 5、比特币日内一度跌破65000美元，触发约2.3 亿美元多头清算，美股加密货币概念股盘前走低。 6、诺和诺德股价下跌13%，跌至2021年6月以来最 低水平，因试验效果不及礼来。 7、美股盘前芯片 半导体板块走低，台 ...

Group 1 - Gilead Sciences announced the acquisition of cancer therapy developer Arcellx for a total equity value of $7.8 billion [1] - Following the announcement, Arcellx's stock price surged by 77.8% in pre-market trading, reaching $113.99 [1] - Gilead will pay $115 in cash per share, along with an additional $5 per share in contingent value rights, representing an 87% premium over Arcellx's previous closing price [1]

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. has announced significant progress in its core product, iza-bren (EGFR×HER3 bispecific antibody ADC), achieving dual primary endpoints in a Phase III clinical trial for locally advanced or metastatic triple-negative breast cancer [1] Group 1 - The independent data monitoring committee (iDMC) recommended early submission based on existing results and regulatory communication, while continuing to follow up with participants [1] - Top-line data indicates that iza-bren significantly extends progression-free survival (PFS) and overall survival (OS) for patients with inoperable locally advanced or metastatic triple-negative breast cancer who have previously failed taxane treatment [1] - This Phase III clinical study is the third to achieve primary endpoints for the bispecific antibody ADC and is the first globally to report dual positive results for PFS/OS in triple-negative breast cancer treatment [1] Group 2 - Iza-bren has seven indications included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and has received a similar designation from the U.S. FDA [2] - Two marketing applications for treating nasopharyngeal carcinoma and esophageal squamous cell carcinoma have been accepted and prioritized by the NMPA's Center for Drug Evaluation (CDE) [2]

证券研究报告|海外策略周报 [Table_Date] 2026 年 2 月 22 日 [Table_Title] 本周亚太市场震荡较多 全球主要市场表现 | [Table_Market1] 指数 | 收盘价 | 周涨跌 | 周涨跌 | | --- | --- | --- | --- | | | | | 幅(%) | | 韩国综合指数 | 5,808.53 | 301.52 | 5.48 | | 胡志明指数 | 1,824.09 | 68.60 | 3.91 | | 法国 CAC40 | 8,515.49 | 203.75 | 2.45 | | 欧元区 STOXX50(欧元) | 6,131.31 | 146.08 | 2.44 | | 英国富时 100 | 10,686.89 | 240.54 | 2.30 | | 加拿大 S&P/TSX 综合 | 33,817.51 | 743.80 | 2.25 | | 巴西 IBOVESPA 指数 | 190,534.42 | 4,070.12 | 2.18 | | 富时新加坡海峡指数 | 5,017.60 | 79.82 | 1.62 | | 纳斯达克指数 | 22, ...